Estimation of the Budget Saving Potential Due to the Introduction of an Etanercept Biosimilar (SB4) for the Treatment of Approved Adult Etanercept Indications in Belgium
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.740
https://www.valueinhealthjournal.com/article/S1098-3015(17)31074-4/fulltext
Title :
Estimation of the Budget Saving Potential Due to the Introduction of an Etanercept Biosimilar (SB4) for the Treatment of Approved Adult Etanercept Indications in Belgium
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31074-4&doi=10.1016/j.jval.2017.08.740
First page :
A529
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
705